To drive a turnaround in trials for ALS and other neurological diseases, we at Modality advocate for new tools that increase understanding of the course of disease and response to treatment. Together with MGH, Everything ALS, and, more recently, Verge Genomics, Modality’s platform is building the most comprehensive audio/visual dataset of people living with ALS. In this 45-minute call, we discuss advancements in digital endpoints in clinical trials and the potential to accelerate clinical research. Our special guest is Karl Kieburtz, MD, MPH, Co-Founder and Chair of Clintrex and principal investigator for numerous multi-center trials in neurology.